AC2993 LARGoal: Sustained-Release Treatment for Type 2 Diabetes

• Unique opportunity for long-acting sustained release

  • Glucose dependent actions
  • Extremely potent with long half-life

• Phase 2 study ongoing

• Working with Alkermes on various sustained-releaseformulations

Placebo

AC2993

p < 0.05

Continuous Infusion of AC2993

crossover study (n=11)

Plasma glucose (mg/dL)

40

80

120

160

200

240

280

0

4

8

12

16

20

24

Time (hr)

AC2993 reaches steady state

meal

Previous slide

Next slide

Back to first slide

View graphic version